This month we hear from the European Commissioner for Health on the burden European countries face from chronic diseases.

Dr Vytenis Andriukaitis tells of his concern about the growth in conditions such as cardiovascular diseases, cancer and type 2 diabetes, and how EU Member States need to be supported if they are to be tackled. 

We look at the future of pharmaceutical marketing, where creating value will be key if the discipline is to be fit-for-purpose in the coming years. 

A crucial part of that will be how companies choose to define ‘value’ and what ‘effective’ looks like as the global pharmaceutical industry faces a series of defining moments.

There’s also a big-picture look in this month’s PME at how companies that are ready for change might transform their very business model.

As Professor Brian D Smith notes, it will be difficult, but it is still doable, and he sets out a five-step process for beginning down that path.